- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Royce & Associates LP Invests $5.50 Million in Cytokinetics
Institutional investor buys 100,083 shares of biopharmaceutical company
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
Royce & Associates LP, an institutional investor, has bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK), acquiring 100,083 shares valued at approximately $5,501,000. This represents approximately 0.08% ownership of Cytokinetics as of the most recent SEC filing.
Why it matters
This investment by Royce & Associates LP, a respected institutional investor, signals confidence in Cytokinetics' potential as a biopharmaceutical company. The purchase of a significant stake could indicate the investor's belief in the company's future growth and development of its drug pipeline.
The details
According to the 13F filing with the SEC, Royce & Associates LP bought the new position in Cytokinetics during the third quarter. Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function, with a focus on both cardiac and skeletal muscle targets.
- Royce & Associates LP bought the new position in Cytokinetics during the third quarter.
The players
Royce & Associates LP
An institutional investor that bought a new position in shares of Cytokinetics, Incorporated.
Cytokinetics, Incorporated
A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.
The takeaway
This investment by a respected institutional investor like Royce & Associates LP suggests confidence in Cytokinetics' potential as a biopharmaceutical company and its ability to develop innovative muscle-modulating therapies. The purchase of a significant stake could signal the investor's belief in the company's future growth and development.
